Lentiviral vectors with CMV or MHCII promoters administered in vivo: Immune reactivity versus persistence of expression

Molecular Therapy

Volumn 15, Issue 7, 2007, Pages 1390-1399

  Kimura, Takahiro ^a   Koya, Richard C ^a   Anselmi, Laura ^a   Sternini, Catia ^a   Wang, He Jing ^b   Comin Anduix, Begonya ^a   Prins, Robert M ^a   Faure Kumar, Emmanuelle ^a   Rozengurt, Nora ^b   Cui, Yan ^c   Kasahara, Noriyuki ^a   Stripecke, Renata ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; LENTIVIRUS VACCINE; LENTIVIRUS VECTOR; LUCIFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA VACCINE; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BIOLUMINESCENCE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; IN VIVO STUDY; INFLAMMATION; MELANOMA B16; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SPLEEN CELL; SPLEEN DISEASE; TRANSGENE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LENTIVIRUS; LIVER; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); SENSITIVITY AND SPECIFICITY; SPLEEN; SURVIVAL RATE; TRANSGENES; VACCINATION; VIRUS INTERNALIZATION;

CYTOMEGALOVIRUS; MUS; VESICULAR STOMATITIS VIRUS;

EID: 34250702619     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300180     Document Type: Article

References (43)

1. + monocytes generates dendritic cells in vitro. Hum Gene Ther 15: 733-748.
2. Koya, RC, Kasahara, N, Favaro, PM, Lau, R, Ta, HQ, Weber, JS et al. (2003). Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 26: 451-460.
3. Dyall, J, Latouche, JB, Schnell, S and Sadelain, M (2001). Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97 114-121.
4. Gruber, A, Kan-Mitchell, J, Kuhen, KL, Mukai, T and Wong-Staal, F (2000). Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96: 1327-1333.
5. He, Y, Zhang, J, Mi, Z, Robbins, P and Falo, LD Jr. (2005). Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174: 3808-3817.
6. Pan, D, Gunther, R, Duan, W, Wendell, S, Kaemmerer, W, Kafri, T et al. (2002). Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 6: 19-29.
7. Ohashl, K, Park F, Schwall, R and Kay, M (2002). Efficient gene transduction to cultured hepatocytes by HIV-1 derived lentiviral vector. Transplant Proc 34: 1431-1433.
8. VandenDriessche, T, Thorrez, L, Naldini, L, Follenzi, A Moons, L, Bememan, Z et al. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100: 813-822.
9. De Palma, M, Venneri, MA and Naldini, L (2003). In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 14: 1193-1206.
10. Follenzi, A, Sabatino, G, Lombardo, A, Boccaccio, C and Naldini, L (2002). Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 13 243-260.
11. Follenzi, A, Battaglia, M, Lombardo, A, Annoni, A, Roncarolo, MG and Naldini, L (2004). Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103 3700-3709.
12. Cronin, J, Zhang, XY and Reiser, J (2005). Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5: 387-398.
13. Firat, H, Zennou, V, Garcia-Pons, F, Ginhoux, F, Cochet, M, Danos, O et al. (2002). Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 4: 38-45.
14. Palmowski, MJ, Lopes, L, Ikeda, Y, Salio, M, Cerundolo, V and Collins, MK (2004). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 172: 1582-1587.
15. Esslinger, C, Chapatte, L, Finke, D, Miconnet, I, Guillaume, P, Levy, F et al. (2003). in vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111: 1673-1681.
16. He, Y, Zhang, J, Donahue, C and Falo, LD Jr. (2006). Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24: 643-656.
17. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13.
18. Schamboeck, A, Korman, AJ, Kamb, A and Strominger, JL (1983). Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain. Nucleic Acids Res 11: 8663-8675.
19. Cui, Y, Golob, J, Kelleher, E, Ye, Z, Pardoll, D and Cheng, L (2002). Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99: 399-408.
20. Prosch, S, Staak K, Stein, J, Liebenthal, C, Stamminger, T, Volk, HD et al. (1995). Stimulation of the human cytomegalovirus IE enhancer/ promoter in HL-60 cells by TNFα is mediated via induction of NF-κB. Virology 208: 197-206.
21. van de Loo, FA, de Hooge, AS, Smeets, RL, Bakker, AC, Bennink, MB, Arntz, OJ et al. (2004). An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther 11: 581-590.
22. LeibundGut-Landmann, S, Waldburger, JM, Krawczyk, M, Otten, LA, Suter, T, Fontana, A et al. (2004). Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34: 1513-1525.
23. Follenzi, A, Ailles, LE, Bakovic, S, Geuna, M and Naldini, L (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222.
24. Sirven, A, Pflumio, F, Zennou, V, Titeux, M, Vainchenker, W, Coulombel, L et al. (2000). The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96: 4103-4110.
25. Stripecke, R, Koya, RC, Ta, HQ, Kasahara, N and Levine, AM (2003). The use of lentiviral vectors in gene therapy of leukemia: Combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors. Blood Cells Mol Dis 31: 28-37.
26. Stripecke, R, Carmen Villacres, M, Skelton, D, Satake, N, Halene, S and Kohn, D (1999). Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6: 1305-1312.
27. Leenen, PJ, Radosevic, K, Voerman, JS, Salomon, B, van Rooijen, N, Klatzmann, D et al. (1998). Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 160 2166-2173.
28. Wang, RF, Appella, E, Kawakami, Y, Kang, X and Rosenberg, SA (1996). Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216.
29. Parkhurst, MR, Fitzgerald, EB, Southwood, S, Sette, A, Rosenberg, SA and Kawakami, Y (1998). Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58: 4895-4901.
30. Bloom, MB, Perry-Lalley, D, Robbins, PF, Li, Y, el-Gamil, M, Rosenberg, SA et al. (1997). Identification of tyrosinase-reiated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185: 453-459.
31. Xie, Z, Cao, Y, Zhang, W, Ye, X, Yu, B and Zheng, Z (2001). Endocytic routes of exogenous antigen in murine dendritic cells and macrophages. Chin Med J (Engl) 114: 93-96.
32. Krishnan, M, Park, JM, Cao, F, Wang, D, Paulmurugan, R, Tseng, JR et al. (2006). Effects of epigenetic modulation on reporter gene expression: Implications for stem cell imaging. FASEB J 20: 106-108.
33. Lee, Y, Sohn, WJ, Kim, DS and Kwon, HJ (2004). NF-κB- and c-Jun-dependent regulation of human cytomegalovirus immediate-early gene enhancer/promoter in response to lipopolysaccharide and bacterial CpG-oligodeoxynucleotides in macrophage cell line RAW 264.7. Eur J Biochem 271: 1094-1105.
34. Sallusto, F, Cella, M, Danieli, C and Lanzavecchia, A (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 182: 389-400.
35. Inaba, K, Witmer-Pack, M, Inaba, M, Hathcock, KS, Sakuta, H, Azuma, M et al. (1994). The tissue distribution at the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180: 1849-1860.
36. Lutz, MB, Suri, RM, Niimi, M, Ogilvie, AL, Kukutsch, NA, Rossner, S et al. (2000). Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30: 1813-1822.
37. Hawiger, D, Inaba, K, Dorsett, Y, Guo, M, Mahnke, K, Rivera, M et al. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779.
38. Steinman, RM (2003). The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) 51: 59-60.
39. Landmann, S, Muhlethaler-Mottet A. Bernasconi, L, Suter, T, Waldburger JM, Mastemak K et al. (2001). Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 194: 379-391.
40. Rodriguez-Pinto, D (2005). B cells as antigen presenting cells. Cell Immunol 238: 67-75.
41. Alderuccio, F, Murphy, K and Toh, BH (2003). Stem cells engineered to express self-antigen to treat autoimmunity. Trends Immunol 24 176-180.
42. Sastry, L, Johnson, T, Hobson, MJ, Smucker, B and Cometta, K (2002). Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 9: 1155-1162.
43. Prins, RM, Odesa, SK and Liau, LM (2003). Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63: 8487-8491.